NCT06269627View on ClinicalTrials.gov

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

PHASE4RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Alcohol Use Disorder
Interventions
DRUG

Acamprosate calcium

Two oral capsules (packaged as one) containing 666 mg of acamprosate calcium will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.

OTHER

Placebo

Two oral capsules (packaged as one) containing 666 mg of inactive substance (e.g., sugar) will be given three times a day (total daily dose: 1998 mg/day) for a total of 21 days.

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH